Your browser doesn't support javascript.
loading
The CD44/COL17A1 pathway promotes the formation of multilayered, transformed epithelia.
Kozawa, Kei; Sekai, Miho; Ohba, Kenji; Ito, Shoko; Sako, Hiroaki; Maruyama, Takeshi; Kakeno, Mai; Shirai, Takanobu; Kuromiya, Keisuke; Kamasaki, Tomoko; Kohashi, Koki; Tanaka, Shinya; Ishikawa, Susumu; Sato, Nanami; Asano, Shota; Suzuki, Hironori; Tanimura, Nobuyuki; Mukai, Yohei; Gotoh, Noriko; Tanino, Mishie; Tanaka, Shinya; Natsuga, Ken; Soga, Tomoyoshi; Nakamura, Tomonori; Yabuta, Yukihiro; Saitou, Mitinori; Ito, Takahiro; Matsuura, Kenkyo; Tsunoda, Makoto; Kikumori, Toyone; Iida, Tadashi; Mizutani, Yasuyuki; Miyai, Yuki; Kaibuchi, Kozo; Enomoto, Atsushi; Fujita, Yasuyuki.
Affiliation
  • Kozawa K; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Cell Pharmacology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical
  • Sekai M; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; KAN Research Institute, Inc., Kobe, Japan.
  • Ohba K; KAN Research Institute, Inc., Kobe, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Ito S; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; KAN Research Institute, Inc., Kobe, Japan.
  • Sako H; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; KAN Research Institute, Inc., Kobe, Japan.
  • Maruyama T; KAN Research Institute, Inc., Kobe, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Kakeno M; KAN Research Institute, Inc., Kobe, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Shirai T; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Kuromiya K; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Kamasaki T; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Kohashi K; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Tanaka S; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Ishikawa S; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Sato N; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Asano S; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Suzuki H; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Tanimura N; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
  • Mukai Y; KAN Research Institute, Inc., Kobe, Japan.
  • Gotoh N; Division of Cancer Cell Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
  • Tanino M; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Tanaka S; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Natsuga K; Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Soga T; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
  • Nakamura T; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan; Department of Anatomy and Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Yabuta Y; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan; Department of Anatomy and Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Saitou M; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan; Department of Anatomy and Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Ito T; Division of Cell Fate Dynamics and Therapeutics, Department of Biosystems Science, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Matsuura K; Division of Cell Fate Dynamics and Therapeutics, Department of Biosystems Science, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Tsunoda M; Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Kikumori T; Department of Breast and Endocrine Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Iida T; Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Mizutani Y; Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Miyai Y; Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kaibuchi K; Department of Cell Pharmacology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Institute for Comprehensive Medical Science (ICMS), Fujita Health University, Toyoake, Japan.
  • Enomoto A; Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Fujita Y; Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan. Electronic address: fujita@monc.med.kyoto-u.ac.jp.
Curr Biol ; 31(14): 3086-3097.e7, 2021 07 26.
Article in En | MEDLINE | ID: mdl-34087104
ABSTRACT
At the early stage of cancer development, oncogenic mutations often cause multilayered epithelial structures. However, the underlying molecular mechanism still remains enigmatic. By performing a series of screenings targeting plasma membrane proteins, we have found that collagen XVII (COL17A1) and CD44 accumulate in RasV12-, Src-, or ErbB2-transformed epithelial cells. In addition, the expression of COL17A1 and CD44 is also regulated by cell density and upon apical cell extrusion. We further demonstrate that the expression of COL17A1 and CD44 is profoundly upregulated at the upper layers of multilayered, transformed epithelia in vitro and in vivo. The accumulated COL17A1 and CD44 suppress mitochondrial membrane potential and reactive oxygen species (ROS) production. The diminished intracellular ROS level then promotes resistance against ferroptosis-mediated cell death upon cell extrusion, thereby positively regulating the formation of multilayered structures. To further understand the functional role of COL17A1, we performed comprehensive metabolome analysis and compared intracellular metabolites between RasV12 and COL17A1-knockout RasV12 cells. The data imply that COL17A1 regulates the metabolic pathway from the GABA shunt to mitochondrial complex I through succinate, thereby suppressing the ROS production. Moreover, we demonstrate that CD44 regulates membrane accumulation of COL17A1 in multilayered structures. These results suggest that CD44 and COL17A1 are crucial regulators for the clonal expansion of transformed cells within multilayered epithelia, thus being potential targets for early diagnosis and preventive treatment for precancerous lesions.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cell Transformation, Neoplastic / Hyaluronan Receptors / Non-Fibrillar Collagens / Epithelium Type of study: Screening_studies Limits: Animals / Humans Language: En Journal: Curr Biol Journal subject: BIOLOGIA Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cell Transformation, Neoplastic / Hyaluronan Receptors / Non-Fibrillar Collagens / Epithelium Type of study: Screening_studies Limits: Animals / Humans Language: En Journal: Curr Biol Journal subject: BIOLOGIA Year: 2021 Document type: Article